The EMA’s recommendation follows evidence that the targeted therapy improves progression-free survival in patients whose tumors have become resistant to endocrine treatment.
Medscape News Europe
Source link : https://www.medscape.com/viewarticle/europe-moves-forward-esr1-driven-breast-cancer-2025a1000vrr?src=rss
Author :
Publish date : 2025-11-14 16:14:00
Copyright for syndicated content belongs to the linked Source.
